Literature DB >> 23077007

FXTAS: new insights and the need for revised diagnostic criteria.

Emmanuelle Apartis1, Anne Blancher, Wassilios G Meissner, Lucie Guyant-Maréchal, David Maltête, Thomas De Broucker, André-Pierre Legrand, Hichem Bouzenada, Hung Tran Thanh, Magali Sallansonnet-Froment, Adrien Wang, François Tison, Carole Roué-Jagot, Frédéric Sedel, Perrine Charles, Sandra Whalen, Delphine Héron, Stéphane Thobois, Alice Poisson, Gaetan Lesca, Anne-Marie Ouvrard-Hernandez, Valérie Fraix, Stephane Palfi, Marie-Odile Habert, Bertrand Gaymard, Jean-Claude Dussaule, Pierre Pollak, Marie Vidailhet, Alexandra Durr, Jean-Claude Barbot, Véronique Gourlet, Alexis Brice, Mathieu Anheim.   

Abstract

OBJECTIVE: Fragile X-associated tremor ataxia syndrome (FXTAS) is defined by FMR1 premutation, cerebellar ataxia, intentional tremor, and middle cerebellar peduncle (MCP) hyperintensities. We delineate the clinical, neurophysiologic, and morphologic characteristics of FXTAS.
METHODS: Clinical, morphologic (brain MRI, (123)I-ioflupane SPECT), and neurophysiologic (tremor recording, nerve conduction studies) study in 22 patients with FXTAS, including 4 women.
RESULTS: A total of 43% of patients had no family history of fragile X syndrome (FXS), which contrasts with previous FXTAS series. A total of 86% of patients had tremor and 81% peripheral neuropathy. We identified 3 electroclinical tremor patterns: essential-like (35%), cerebellar (29%), and parkinsonian (12%). Two electrophysiologic patterns evocative of non-length-dependent (56%) and length-dependent sensory neuropathy (25%) were identified. Corpus callosum splenium (CCS) hyperintensity was as frequent (68%) as MCP hyperintensities (64%). Sixty percent of patients had parkinsonism and 47% abnormal (123)I-ioflupane SPECT. Unified Parkinson's Disease Rating Scale motor score was correlated to abnormal (123)I-ioflupane SPECT (p = 0.02) and to CGG repeat number (p = 0.0004). Scale for the assessment and rating of ataxia correlated with dentate nuclei hyperintensities (p = 0.03) and CCS hyperintensity was a marker of severe disease progression (p = 0.04).
CONCLUSIONS: We recommend to include in the FXTAS testing guidelines both CCS hyperintensity and peripheral neuropathy and to consider them as new major radiologic and minor clinical criterion, respectively, for the diagnosis of FXTAS. FXTAS should also be considered in women or when tremor, MCP hyperintensities, or family history of FXS are lacking. Our study broadens the spectrum of tremor, peripheral neuropathy, and MRI abnormalities in FXTAS, hence revealing the need for revised criteria.

Entities:  

Mesh:

Year:  2012        PMID: 23077007     DOI: 10.1212/WNL.0b013e318271f7ff

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  67 in total

1.  Immune mediated disorders in women with a fragile X expansion and FXTAS.

Authors:  Isha Jalnapurkar; Nuva Rafika; Flora Tassone; Randi Hagerman
Journal:  Am J Med Genet A       Date:  2014-11-14       Impact factor: 2.802

Review 2.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

3.  Which approach is better: bilateral versus unilateral thalamic deep brain stimulation in patients with fragile X-associated tremor ataxia syndrome.

Authors:  R Mehanna; I Itin
Journal:  Cerebellum       Date:  2014-04       Impact factor: 3.847

4.  Small fiber neuropathy in a woman with fragile X-associated tremor/ataxia syndrome (FXTAS).

Authors:  Jean-Baptiste Chanson; Nelly Boehm; Brigitte Samama; Andoni Echaniz-Laguna; Mathieu Anheim
Journal:  J Neurol       Date:  2014-12-09       Impact factor: 4.849

5.  Relevance of corpus callosum splenium versus middle cerebellar peduncle hyperintensity for FXTAS diagnosis in clinical practice.

Authors:  Mathilde Renaud; Julien Perriard; Sarah Coudray; Mathieu Sévin-Allouet; Christophe Marcel; Wassilios G Meissner; Jean-Baptiste Chanson; Nicolas Collongues; Nathalie Philippi; Odile Gebus; Véronique Quenardelle; Anna Castrioto; Paul Krack; Karine N'Guyen; François Lefebvre; Andoni Echaniz-Laguna; Jean-Philippe Azulay; Nicolas Meyer; Pierre Labauge; Christine Tranchant; Mathieu Anheim
Journal:  J Neurol       Date:  2014-12-02       Impact factor: 4.849

6.  Consensus paper: radiological biomarkers of cerebellar diseases.

Authors:  Leonardo Baldarçara; Stuart Currie; M Hadjivassiliou; Nigel Hoggard; Allison Jack; Andrea P Jackowski; Mario Mascalchi; Cecilia Parazzini; Kathrin Reetz; Andrea Righini; Jörg B Schulz; Alessandra Vella; Sara Jane Webb; Christophe Habas
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

Review 7.  [Fragile X associated tremor/ataxia syndrome: its clinical presentation, pathology, and treatment].

Authors:  M J Salcedo-Arellano; R J Hagerman; V Martinez-Cerdeno
Journal:  Rev Neurol       Date:  2019-03-01       Impact factor: 0.870

8.  Tremor-Predominant Fragile X-Associated Tremor/Ataxia Syndrome in a Female.

Authors:  Veronica Bruno; Susan H Fox
Journal:  Mov Disord Clin Pract       Date:  2014-12-30

9.  Characterization and Early Detection of Balance Deficits in Fragile X Premutation Carriers With and Without Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS).

Authors:  Joan A O'Keefe; Erin Robertson-Dick; Emily J Dunn; Yan Li; Youping Deng; Amber N Fiutko; Elizabeth Berry-Kravis; Deborah A Hall
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

10.  CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.

Authors:  Anna Lisa Ludwig; Glenda M Espinal; Dalyir I Pretto; Amanda L Jamal; Gloria Arque; Flora Tassone; Robert F Berman; Paul J Hagerman
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.